(Reuters) – Eli Lilly and Co reported a 31% fall in quarterly profit on Thursday, hurt by lower prices of diabetes drug Humalog and Insulin Lispro injection.
The company’s net income fell to $952.5 million, or $1.05 per share, in the second quarter ended June 30, from $1.39 billion, or $1.53 per share, a year earlier.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
